Is Major Move Coming For RepliCel Life Sciences Inc After This Gap Down?

 Is Major Move Coming For RepliCel Life Sciences Inc After This Gap Down?

The stock of RepliCel Life Sciences Inc (CVE:RP) gapped down by $0.03 today and has $0.77 target or 8.00% below today’s $0.84 share price. The 5 months technical chart setup indicates high risk for the $11.38 million company. The gap down was reported on Nov, 28 by Barchart.com. If the $0.77 price target is reached, the company will be worth $910,400 less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. About 23,000 shares traded hands or 93.39% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.

More recent RepliCel Life Sciences Inc (CVE:RP) news were published by: Marketwired.com which released: “RepliCel Life Sciences Announces Closing of Private Placement” on October 31, 2016. Also Midasletter.com published the news titled: “RepliCel Life Sciences Inc. CEO David Hall Interview and Podcast” on October 23, 2014. Prnewswire.com‘s news article titled: “RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype” with publication date: July 29, 2015 was also an interesting one.

RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $11.38 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment